Vincenzo Carnovale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4429110/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics, 2021, 10, 338.	3.7	50
2	Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Respiratory Medicine, 2021, 189, 106646.	2.9	26
3	Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study. Journal of Clinical Medicine, 2022, 11, 1021.	2.4	25
4	Lung structure and function similarities between primary ciliary dyskinesia and mild cystic fibrosis: a pilot study. Italian Journal of Pediatrics, 2017, 43, 34.	2.6	21
5	Cystic Fibrosis: The Sense of Smell. American Journal of Rhinology and Allergy, 2020, 34, 35-42.	2.0	17
6	Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study. Respiratory Medicine, 2018, 138, 88-94.	2.9	13
7	Effectivenesss of ivacaftor in severe cystic fibrosis patients and nonâ€G551D gating mutations. Pediatric Pulmonology, 2019, 54, 1398-1403.	2.0	13
8	Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. Journal of Cystic Fibrosis, 2022, 21, 850-855.	0.7	12
9	Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1725-1730.	2.3	7
10	The impact of cystic fibrosis on the working life of patients: A systematic review. Journal of Cystic Fibrosis, 2022, 21, 361-369.	0.7	4
11	Employment Status and Work Ability in Adults with Cystic Fibrosis. International Journal of Environmental Research and Public Health, 2021, 18, 11776.	2.6	4
12	Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?. Journal of Cystic Fibrosis, 2021, , .	0.7	3
13	Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation. Respiratory Medicine, 2022, 192, 106736.	2.9	0